PART I Overview We are a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI . Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occur...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001213900-26-018231 | EDGAR | 81K words |
| 2025-03-25 | 2024-12-31 | 0001013762-25-002283 | EDGAR | — |
| 2024-04-04 | 2023-12-31 | 0001213900-24-030053 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001213900-23-024122 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001213900-22-016136 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001213900-21-019233 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001213900-20-007405 | EDGAR | — |
| 2019-08-21 | 2019-06-30 | 0001213900-19-016461 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001213900-25-109186 | EDGAR | 25K words |
| 2025-08-13 | 2025-06-30 | 0001213900-25-075328 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001213900-25-044157 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001213900-24-098523 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001213900-24-068981 | EDGAR | — |
| 2024-05-20 | 2024-03-31 | 0001213900-24-045273 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001213900-23-086662 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001213900-23-064926 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001213900-23-039734 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001213900-22-070435 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001213900-22-046257 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001213900-22-025542 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001213900-26-038095 | EDGAR | 10K words |
| 2026-03-27 | 0001213900-26-035605 | EDGAR | — |
| 2026-03-19 | 0001213900-26-031587 | EDGAR | — |
| 2026-03-11 | 0001213900-26-026174 | EDGAR | — |
| 2026-03-06 | 0001213900-26-024344 | EDGAR | — |
| 2026-03-02 | 0001213900-26-022301 | EDGAR | — |
| 2026-02-25 | 0001213900-26-020374 | EDGAR | — |
| 2026-02-13 | 0001213900-26-016402 | EDGAR | — |
| 2026-02-10 | 0001213900-26-014298 | EDGAR | — |
| 2026-01-14 | 0001213900-26-004348 | EDGAR | — |
172 total filings indexed. 142 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001739174 |
| Ticker | PHGE |
| Exchange | NYSE |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.biomx.com |
| Listed | 2019-03-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report